About half to two-thirds of people with Graves' disease who are treated with antithyroid drugs or perchlorate eventually see their thyroid antibodies return to normal levels within two years, no matter which drug they take or how much they take. This finding is from the abstract summary - full study details were not available
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine the pooled proportion of Graves' patients achieving TSI normalization across all treatment modalities and durations.
A systematic review and meta-analysis of all prospective studies reporting TSI normalization rates in Graves' disease patients treated with thionamides, radioiodine, or surgery, with standardized definitions of normalization (e.g., TSI <130% of control) and minimum 12-month follow-up (n≥20 studies, ≥2000 patients).
An RCT could compare the rate of TSI normalization between different drug regimens to determine if dosage or duration influences outcome.
A multicenter RCT of 300 Graves' patients randomized to methimazole 10 mg, 20 mg, or 30 mg daily for 24 months, with TSI measured at 6, 12, and 24 months. Primary outcome: proportion achieving TSI normalization at 24 months.
A prospective cohort could estimate the real-world rate of TSI normalization in untreated vs. treated Graves' disease over time.
A prospective cohort of 500 adults with newly diagnosed Graves' disease, followed for 24 months with monthly TSI, T4, T3, and TSH measurements, stratified by treatment type and adherence, to estimate cumulative incidence of TSI normalization.
Could compare characteristics of patients who normalized TSI vs. those who did not to identify predictors.
A case-control study comparing 100 patients with TSI normalization at 24 months to 100 without, matched for age and baseline TSI, analyzing treatment duration, drug dose, TSH suppression, and HLA type.
Could estimate the prevalence of TSI normalization in a population of treated Graves' patients at a single time point.
A cross-sectional survey of 400 adults with prior Graves' disease treated with thionamides for ≥12 months, measuring current TSI levels and treatment history.